Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03462641 · ClinicalTrials.gov registry record · Phase 1
Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm
A Phase 1 study, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT03462641 is a Phase 1 study that has completed, run by University of Michigan. The registered enrollment target is 36 participants.
The verdict
NCT03462641, a Phase 1 study, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This arm is a positron emission tomography (PET) biomechanistic GABA-A receptor target engagement study that includes detailed clinical and motor assessments before and after the i.v. administration of 1 mg flumazenil or placebo in Parkinson disease subjects. Each subject will receive 1mg flumazenil or placebo at two visits.
Interventions
- DRUG Placebo
- DRUG Flumazenil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2018-03-09 |
| Est. Completion | 2021-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03462641
The ClinicalTrials.gov registry entry for NCT03462641 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03462641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03462641 about?
NCT03462641 is a clinical study titled "Modulation of GABA-A Receptors in Parkinson Disease-Flumazenil Arm". This arm is a positron emission tomography (PET) biomechanistic GABA-A receptor target engagement study that includes detailed clinical and motor assessments before and after the i.v. administration of 1 mg flumazenil or placebo in Parkinson disease subjects. Each subject will receive 1mg flumazenil...
What is the current status of trial NCT03462641?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2018-03-09. Estimated completion is 2021-06-04.
What interventions are being tested in trial NCT03462641?
The interventions under investigation include: Placebo (DRUG), Flumazenil (DRUG).
Who is sponsoring clinical trial NCT03462641?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.